Biopharma’s recent string of CEO splits

Leaders at Bavarian Nordic, Sarepta and Alkermes recently announced plans to step down.

By Meagan Parrish • March 6, 2026

Cancer tests are becoming more precise and guiding pharma R&D

Abbott’s major takeover of Exact Sciences showcases a rising push to leverage cancer tests in precision oncology therapy and R&D. 

By Michael Gibney • March 5, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

What 3 recent FDA rejections reveal about shifts inside the agency

The FDA’s approval strategy has been difficult to pin down, but recent decisions provide clues for how some of the most volatile initiatives will play out.

By Alexandra Pecci • March 4, 2026

Inside the race to thwart the dramatic rise in early-onset colorectal cancer

The increasingly common disease still presents a major challenge in oncology.

By Kelly Bilodeau • March 4, 2026

J&J’s blockbuster Spravato is setting the stage for managing psychedelics’ risks

Spravato became a blockbuster despite ketamine’s dangerous abuse history, causing doctors to balance the real-world implications of its use.

By Michael Gibney • March 3, 2026

Big Pharma’s next entrant could come from China

Companies with a growing international presence like Jiangsu Hengrui Pharmaceuticals are on their way to joining the big leagues.

By Kelly Bilodeau • March 2, 2026

How PBM reforms could push drugmakers into the pricing spotlight

The Consolidated Appropriations Act's landmark PBM overhaul removes financial incentives tied to pharma list prices, potentially leaving drugmakers to defend their own practices.

By Alivia Kaylor • Feb. 27, 2026

Biohaven says FDA roadblocks leave rare disease patients in limbo

An FDA rejection last year for a rare disease drug from Biohaven reflects the amount of work left to get patients the treatments they need, the company says.

By Michael Gibney • Feb. 26, 2026

Will the FDA yank mRNA vaccines?

Adding increased obstacles and sowing safety doubts may be enough to chill mRNA vaccine use and development.

By Alexandra Pecci • Feb. 24, 2026

No one-trick pony in oncology, Merck’s cancer footprint is expanding

The three key therapeutic approaches Merck is leveraging to craft its next era in cancer care.

By Meagan Parrish • Feb. 20, 2026

Will vaccine regulatory uncertainty chill innovation? Pharma execs sound off.

Moderna’s clash with U.S. health agencies over its flu shot reflects a difficult time for vaccinemakers, but many are still playing the waiting game.

By Michael Gibney • Feb. 19, 2026

AI is slashing jobs across industries. Will pharma be next?

Despite a wave of AI-fueled layoffs, the pharma and biotech industries could be spared from massive job losses for now.

By Alexandra Pecci • Feb. 18, 2026

Pharma could be on the cusp of finally breaking the blood-brain barrier

Denali’s brain shuttle technology is poised for a potential landmark approval in April, and other options are gaining ground. 

By Kelly Bilodeau • Feb. 18, 2026

More drugmakers are turning to cancer combos. Will it help patients live longer?

Researchers are increasingly trying multi-pronged approaches to stop tumors in their tracks, leaving monotherapies to the wayside.

By Kelly Bilodeau • Feb. 17, 2026

Ovid takes another big swing in neuroscience under a new CEO

After multiple setbacks, the company is chasing a CNS target it believes has “revolutionary” potential.

By Meagan Parrish • Feb. 13, 2026

Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief

The move drew skepticism from investors despite multiple recent research setbacks that have left questions about Sanofi’s ability to confront Dupixent’s looming patent expiration.

By Kristin Jensen • Feb. 13, 2026

Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift

The pharma giant’s acquisition of in vivo CAR-T specialist Orna Therapeutics follows similar deals from AbbVie, Gilead, Bristol Myers Squibb and AstraZeneca.

By Michael Gibney • Feb. 12, 2026

A protein model designed for space could expand pharma’s definition of ‘druggability’

A computational biology company that started in space tech is looking to change how biopharma finds disease targets by modeling how proteins behave.

By Michael Gibney • Feb. 11, 2026

New FDA guidance that’s a ‘huge deal’ for clinical trials

Why using Bayesian statistics could transform trial design for rare diseases and beyond.

By Kelly Bilodeau • Feb. 10, 2026

New diagnostics define drug targets for Alzheimer’s, Parkinson’s and beyond

Emerging tests offer a bridge to pharma aiming to treat neurodegenerative diseases in their earlier stages.

By Kelly Bilodeau • Feb. 9, 2026

Bayer sets the stage for a pharma comeback

The pharma giant’s drug sales haven’t wowed in recent years. But that could soon change.

By Meagan Parrish • Feb. 6, 2026

Big Pharma CEOs set sights on massive growth in years to come

The CEOs at Johnson & Johnson, Pfizer and Merck have big plans for future revenue even as they face difficult odds in the here and now.

By Michael Gibney • Feb. 5, 2026

The most valuable up-and-coming GLP-1s

Late-stage GLP-1 candidates from Eli Lilly, Novo Nordisk and Amgen have a combined net present value of $68 billion.

By Alivia Kaylor • Feb. 5, 2026

Why TrumpRx is stumbling before it gets off the ground

Concerns about potential kickbacks, costs and conflicts have triggered calls for oversight.

By Kelly Bilodeau • Feb. 4, 2026

Investors crave safer, market-ready biotech bets, widening the early-stage funding gap

In these difficult financial times, venture capital dollars favor later-stage biotechs, forcing drugmakers with earlier-stage candidates to find alternative funding routes.

By Michael Gibney • Feb. 3, 2026